Nucleos(t)ide analogue therapy reduces risk for HCC recurrence in HBV
Patients with chronic hepatitis B virus infection treated with nucleos(t)ide analogues showed a reduced risk for hepatocellular carcinoma recurrence compared with patients untreated with nucleos(t)ide analogues, according to published findings.
Researchers performed a territorywide cohort study using data from 2,198 patients with chronic HBV and hepatocellular carcinoma (HCC) listed in China’s Hospital Authority database. Of these patients, 968 received treatment with nucleos(t) analogues and 1,230 did not. HCC treatments, nucleos(t) analogue therapy and laboratory parameters were assessed to determine the rate of HCC recurrence and mortality, which was the study’s primary endpoint, according to the research. A 3-month landmark analysis was used to evaluate this outcome in patients who received and did not receive nucleos(t) analogues.
Over a median follow-up of 2.8 years, HCC recurrence occurred in 36.7% and mortality occurred in 47% of the untreated patients, compared with 22.3% and 31.1% in patients who were treated with nucleos(t) analogues, respectively.
Nucleos(t) analogue therapy reduced the risk for overall HCC recurrence (adjusted subhazard ratio (SHR) = 0.63; 95% CI, 0.49–0.8), which was most evident among patients who underwent surgical resection (SHR = 0.58; 95% CI, 0.37–0.91).
In addition, the researchers wrote, the probability of nucleos(t) analogue treatment reducing the risk for mortality (HR = 0.82; 95% CI, 0.64–1.03) was more pronounced among patients who underwent resection (HR = 0.64; 95% CI, 0.41–0.99). Reduced risk was not significant in the other treatment groups.
“Our findings show that nucleos(t)ide analogues treatment reduces the risk of HCC recurrence in patients with chronic hepatitis B treated by surgical resection,” the researchers concluded. – by Melinda Stevens
Disclosure: Healio.com/Hepatology was unable to confirm relevant financial disclosures at the time of publication.